A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
ENSAYO CLINICO COMERCIAL
Información del ensayo clínico
- Promotor: MEDIMMUNE LLC
- Fase: II
- Comienzo de la ejecución: 09/06/2017
- Fin de la ejecución: 31/12/2019
- IP: JOSE ANTONIO HURTADO SUAZO